Skip to main content

Biogen TECFIDERA revenue

  • BIIB · Nasdaq
  • Biotechnology
  • S&P 500
$253.40+1.17%Close 13 Nov 2026 · Market value $37.59B

TECFIDERA revenue at Biogen came to $82.0M for the quarter to 30 Sep 2026, down 51.2% from a year earlier.

As Biogen reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 28 Oct 2026.

By quarter

$244.3MDec 2023$254.3MMar 2024$252.2MJun 2024$232.8MSep 2024$227.8MDec 2024$206.1MMar 2025$193.6MJun 2025$168.2MSep 2025$111.8MDec 2025$109.5MMar 2026$90.9MJun 2026$82.0MSep 2026
Biogen TECFIDERA revenue, every reported period
Period endingTECFIDERA revenueChange on a yearFiled
30 Sep 2026$82.0Mdown 51.2%28 Oct 2026
30 Jun 2026$90.9Mdown 53.0%29 Jul 2026
31 Mar 2026$109.5Mdown 46.9%29 Apr 2026
31 Dec 2025$111.8Mdown 50.9%6 Feb 2026
30 Sep 2025$168.2Mdown 27.7%30 Oct 2025
30 Jun 2025$193.6Mdown 23.2%31 Jul 2025
31 Mar 2025$206.1Mdown 19.0%1 May 2025
31 Dec 2024$227.8Mdown 6.8%12 Feb 2025
30 Sep 2024$232.8Mdown 2.8%30 Oct 2024
30 Jun 2024$252.2Mdown 0.8%1 Aug 2024
31 Mar 2024$254.3Mdown 7.4%24 Apr 2024
31 Dec 2023$244.3Mdown 17.8%14 Feb 2024
30 Sep 2023$239.5Mdown 29.4%8 Nov 2023
30 Jun 2023$254.2Mdown 36.1%25 Jul 2023
31 Mar 2023$274.5Mdown 33.0%25 Apr 2023
31 Dec 2022$297.1M—15 Feb 2023
30 Sep 2022$339.0Mdown 32.0%25 Oct 2022
30 Jun 2022$397.9Mdown 18.4%20 Jul 2022
31 Mar 2022$409.9M—3 May 2022
30 Sep 2021$498.6M—20 Oct 2021
30 Jun 2021$487.6M—22 Jul 2021
31 Mar 2020$1.1Bup 10.2%23 Apr 2020
31 Dec 2019$1.2Bup 4.6%6 Feb 2020
30 Sep 2019$1.1Bup 3.0%22 Oct 2019
30 Jun 2019$1.2Bup 5.8%24 Jul 2019
31 Mar 2019$998.8Mup 1.2%24 Apr 2019
31 Dec 2018$1.1B—6 Feb 2019
30 Sep 2018$1.1Bup 1.9%23 Oct 2018
30 Jun 2018$1.1Bdown 2.1%24 Jul 2018
31 Mar 2018$986.9M—24 Apr 2018
30 Sep 2017$1.1B—24 Oct 2017
30 Jun 2017$1.1B—25 Jul 2017

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Biogen: Product revenue, net revenue · MS Product Revenues · Rare Disease Product Revenue · Revenue from anti-CD20 therapeutic programs revenue · SPINRAZA revenue · TYSABRI revenue · Royalty Attributed To OCREVUS revenue · Fumarate revenue · Specialized Immunology revenue · Interferon revenue · VUMERITY revenue · SYFOVRE revenue · SKYCLARYS revenue · Biosimilars revenue · AVONEX revenue · Contract manufacturing, royalty and other revenue · Contract manufacturing revenue · BENEPALI revenue · ZURZUVAE revenue · Alzheimer's Collaboration revenue · PLEGRIDY revenue · EMPAVELI revenue · IMRALDI revenue · QALSODY revenue · financial statements

Every KPI and segment of BIIB, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.